(NASDAQ: KZR) Kezar Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.32%.
Kezar Life Sciences's earnings in 2025 is -$78,634,000.On average, 4 Wall Street analysts forecast KZR's earnings for 2025 to be -$59,816,238, with the lowest KZR earnings forecast at -$75,468,914, and the highest KZR earnings forecast at -$45,442,076. On average, 3 Wall Street analysts forecast KZR's earnings for 2026 to be -$51,335,665, with the lowest KZR earnings forecast at -$60,126,734, and the highest KZR earnings forecast at -$42,008,350.
In 2027, KZR is forecast to generate -$52,053,825 in earnings, with the lowest earnings forecast at -$64,437,156 and the highest earnings forecast at -$39,670,494.